The Effect of Canertinib on Sensitivity of Cytotoxic Drugs in Tamoxifen-Resistant Breast Cancer Cells In Vitro

Figure 5

Measuring of EGFR and c-erbB2 expression; activation of ERK1/2 and AKT in MCF-7, T47D, and their tamoxifen-resistant derivative cells MCF-7(TamR) and T47D (TamR) cells, respectively. (a) Changes in levels of total EGFR and c-erbB2 expression by Western blot. (b) Changes in levels of p-EGFR and p-c-erbB2 expression by Western blot. (c) Changes in levels of expression and activation of ERK1/2 and AKT by Western blot. (d) Changes in levels of EGFR expression and activation in t47d cells before and after the development of tamoxifen resistance by Western blot. (e) The inhibitory effects of canertinib on the activation of EGFR, Akt, and ERK1/2 and their encoded protein in both MCF-7 and MCF-7(TamR) cells by Western blot.

(a)

(b)

(c)

(d)

(e)